Effects of combined therapy with atorvastatin and polyunsaturated omega-3 fatty acids on lipid profile, lipoprotein-associated phospholipase A2 and thromboxane

Aim. To study the effects of the combined therapy with atorvastatin and polyunsaturated omega-3 fatty acids (omega-3 PUFA) on lipid profile, lipoprotein-associated phospholipase A2 (Lp-PLA (2)), and thromboxane B2. Material and methods. The study included 60 patients with coronary heart disease (CHD), randomised into two groups: Group I (n=29) receiving atorvastatin monotherapy; and Group II (n=31) receiving combined therapy with atorvastatin (10 mg/d) and omega-3 PUFA (1 g/d). At baseline, 12 and 24 weeks later, all participants underwent the assessment of lipid profile, serum levels of Lp-PLA (2), and plasma levels of thromboxane B2. Results. Adding omega-3 PUFA to atorvastatin therapy did not change the lipid-lowering action of the latter, with an exception of a greater triglyceride level reduction (-32 %; p=0,001 vs. the baseline). In both groups, six-month therapy was associated with a significant decrease in Lp-PLA (2) level (-33 % and -34 % for monotherapy and combined therapy groups, respectively; р=0,002 for both comparisons). Thromboxane B2 concentration decreased by 26 % (р=0,07) in Group I and by 62 % in Group II (р=0,02), compared to baseline levels. Conclusion. Combined therapy with atorvastatin and omega-3 PUFA was associated with decreased levels of atherogenic lipoproteins, Lp-PLA (2) and thromboxane B2, which can result in cardiovascular risk reduction.

1. Studer M, Briel M, Leimenstoll B, et al. Effect of Different Antilipidemic Agents and Diets on Mortality. A Systematic Review. Arch Intern Med 2005; 165: 725-30.

2. Packard CJ, O’Reilly DS, Caslake MJ, et al. West of Scotland Coronary Prevention Study Group. Lipoprotein- associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000; 343: 1148-55.

3. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997; 65: 1645S-54.

4. Garza CA, Montori VM, McConnell JP, et al. Association Between Lipoprotein-associated Phospholipase A2 and Cardiovascular Disease: A Systematic Reiew. Mayo Clin Proc 2007; 82(2): 159-65.

5. Daniels LB, Laughlin GA, Sarno MJ, et al. LipoproteinAssociated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population: The Rancho Bernardo Study. JACC 2008; 51: 913-9.

6. Packard CJ, O’Reilly DS, Caslake MJ, et al. West of Scotland Coronary Prevention Study Group. Lipoprotein- associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med 2000; 343: 1148-55.

7. Asano K, Okamoto S, Fukunaga K, et al. Cellular source (s) of platelet- activating factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999; 261: 511-4.

8. Caslake MJ, Packard CJ, Sucking KE, et al. Lipoproteinassociated phospholipase A2, platelet- activating factor acetylhydrolase: a potentional new risk factor for coronary artery disease. Atherosclerosis 2000; 150: 413-9.

9. Duda MK, O’shea KM, Tintinu A, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overloadinduced cardiac dysfunction. Cardiovascular Res 2009; 81: 319- 27.

10. Simopoulos AP. The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases. Exp Biol Med 2008; 233: 674-88.